Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC

This trial compares a low-dose immunotherapy approach — a reduced dose of nivolumab (an immune-stimulating drug) combined with standard chemotherapy — against chemotherapy alone for people with advanced or metastatic non-small cell lung cancer (NSCLC) who have not received prior treatment. **You may be eligible if:** - You are 18 or older with a confirmed diagnosis of advanced or metastatic NSCLC (stage IIIB–IV) - You have not previously received treatment for advanced disease (prior early-stage treatment ended at least 6 months ago) - You are in good functional condition (ECOG performance status 0 or 1) - You have at least one measurable tumor - You have adequate organ function (blood counts, kidney, liver) - You agree to use contraception if applicable **You may NOT be eligible if:** - Your cancer has certain genetic mutations (EGFR, ALK, or ROS1) - You have previously received immunotherapy (anti-PD-1 or anti-PD-L1 drugs) - You have active or severe lung disease, autoimmune disease, or serious infection - You are pregnant or breastfeeding - You have active hepatitis B or C, or HIV - You have had another cancer within the past 2 years Talk to your doctor to see if this trial is right for you.